Who
Meghan Fitzgerald
Director
Company insider
Files Form 4 as: Director, Roivant Sciences; Director, Tenet Healthcare; Director, Concert Pharmaceuticals; EVP, Strategy & Health Policy, Cardinal Health; VP and Chief Business Officer, Vion Pharmaceuticals.
In numbers
- Trades disclosed
- 79
- Buys
- 1
- Sells
- 7
- Bought
- $80K
- Sold
- $10.3M
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 10 Jan 2006
- Last trade
- 16 Sep 2026
- Last filed
- 18 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Sep 2026filed 18 Sep 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code A | —5,054 at $0.00 | filing |
| 16 Sep 2026filed 18 Sep 2026 | ROIV Roivant Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,531 at $0.00 | filing |
| 16 Sep 2026filed 18 Sep 2026 | ROIV Roivant Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,531 at $0.00 | filing |
| 16 Sep 2026filed 18 Sep 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code A | —5,054 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Sold | $187K4,712 at $39.68 | filing |
| 15 Sep 2026filed 17 Sep 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Sold | $16K400 at $40.45 | filing |
| 15 Sep 2026filed 17 Sep 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Sold | $187K4,712 at $39.68 | filing |
| 15 Sep 2026filed 17 Sep 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Sold | $16K400 at $40.45 | filing |
| 10 Sep 2026filed 14 Sep 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code F | $71K1,743 at $40.94 | filing |
| 10 Sep 2026filed 14 Sep 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code F | $71K1,743 at $40.94 | filing |
| 8 Sep 2026filed 10 Sep 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code M | $176K20,000 at $8.80 | filing |
| 8 Sep 2026filed 10 Sep 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Sold | $798K20,000 at $39.90 | filing |
| 8 Sep 2026filed 10 Sep 2026 | ROIV Roivant Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 8 Sep 2026filed 10 Sep 2026 | ROIV Roivant Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 8 Sep 2026filed 10 Sep 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code M | $176K20,000 at $8.80 | filing |
| 8 Sep 2026filed 10 Sep 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Sold | $798K20,000 at $39.90 | filing |
| 30 Jun 2026filed 2 Jul 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code M | $88K10,000 at $8.80 | filing |
| 30 Jun 2026filed 2 Jul 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Sold | $349K10,000 at $34.90 | filing |
| 30 Jun 2026filed 2 Jul 2026 | ROIV Roivant Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | ROIV Roivant Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
News
Roivant Sciences Says Brepocitinib Meets Primary Goal In Uveitis Trials; Shares RiseROIV · rttnews.com · 21 Oct 2026Head to Head Analysis: Roivant Sciences (NASDAQ:ROIV) vs. Pharming Group (NASDAQ:PHAR)ROIV · dailypolitical.com · 14 Oct 2026
0 headlines in the last 90 days name Meghan Fitzgerald; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.